"Located in Burlington, NC, the Cone Health Cancer Center at Alamance Regional offers comprehensive, leading-edge services in the area of cancer care. We specialize in the treatment of multiple cancer types including breast cancer, prostate cancer, colon cancer, skin cancer and more."

During the past decade, Cone Health Cancer Center at Alamance Regional conducted 51 clinical trials. In the 10-year time frame, 51 clinical trials started and 68 clinical trials were completed, i.e. on average, 133.3% percent of trials that started reached the finish line to date. In the past 5 years, 13 clinical trials started and 38 clinical trials were completed. i.e. 292.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Cone Health Cancer Center at Alamance Regional" #1 sponsor was "National Cancer Institute (NCI)" with 35 trials, followed by "SWOG Cancer Research Network" with 21 trials sponsored, "Alliance for Clinical Trials in Oncology" with 11 trials sponsored, "Wake Forest University Health Sciences" with 10 trials sponsored and "Gynecologic Oncology Group" with 10 trials sponsored. Other sponsors include 25 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Cone Health Cancer Center at Alamance Regional" #1 collaborator was "National Cancer Institute (NCI)" with 74 trials as a collaborator, "NRG Oncology" with 16 trials as a collaborator, "Cancer and Leukemia Group B" with 5 trials as a collaborator, "North Central Cancer Treatment Group" with 5 trials as a collaborator and "SWOG Cancer Research Network" with 5 trials as a collaborator. Other collaborators include 24 different institutions and companies that were collaborators in the rest 30 trials.

According to Clinical.Site data, the most researched conditions in "Cone Health Cancer Center at Alamance Regional" are "Breast Cancer" (16 trials), "Recurrent Squamous Cell Lung Carcinoma" (9 trials), "Fallopian Tube Endometrioid Adenocarcinoma" (7 trials), "Fallopian Tube Mucinous Adenocarcinoma" (7 trials) and "Fallopian Tube Transitional Cell Carcinoma" (7 trials). Many other conditions were trialed in "Cone Health Cancer Center at Alamance Regional" in a lesser frequency.

Most popular intervention types in "Cone Health Cancer Center at Alamance Regional" are "Drug" (96 trials), "Other" (67 trials), "Biological" (44 trials), "Procedure" (16 trials) and "Radiation" (12 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (40 trials), "Quality-of-Life Assessment" (32 trials), "Paclitaxel" (24 trials), "Carboplatin" (20 trials) and "Bevacizumab" (13 trials). Other intervention names were less common.

The vast majority of trials in "Cone Health Cancer Center at Alamance Regional" are 65 trials for "All" genders, 47 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Cone Health Cancer Center at Alamance Regional". undefined are not yet recruiting, 11 are recruiting, 44 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 49 completed trials in Cone Health Cancer Center at Alamance Regional, 1 suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in Cone Health Cancer Center at Alamance Regional, 3 "Phase 1" clinical trials were conducted, 39 "Phase 2" clinical trials and 73 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 3 trials that are defined as “Not Applicable".